Cyprus’ pharmaceutical services have recalled all medications that contain ranitidine due to concerns that It has possible links with cancer.
The measure has been taken in response to FDA’s announcement of the detection of low levels of NDMA – a carcinogen that is probably present in ranitidine. Tests done on animals have shown that NDMA does indeed have risks of inducing cancer in those consuming it.
Commonly taken for heartburn and minor digestive issues, ranitidine’s main function is to block stomach acid. Products that contain ranitidine include were Zantac injection and tablets, Lumaren injection and tablets, Ranitidine Accord tablets, and Verlost oral solution.
The cease will continue till the European Medicines agency makes its own tests to determine the actual safety of the drug – or lack thereof.
For now, patients who are on said medications on a regular basis have been advised to visit their doctor and/or pharmacist to get tested for issues or to get prescribed an alternative medication.
Both European and U.S. drug regulators are currently reviewing the safety of ranitidine after having made the shockingly breakthrough discovery.
